Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study-论文-万方医学网

Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study

导出原文传递

翻译打印收藏纠错

作者： Chen, Song ^[1] ; Wu, Zhiqiang ^[2] ; Shi, Feng ^[3] ; Mai, Qicong ; Wang, Liguang ; Wang, Fan ; Zhuang, Wenquan ; Chen, Xiaoming ; Chen, Huanwei ; Xu, Bo ; Lai, Jiaming ; Guo, Wenbo

作者单位： Dept Intervent Radiol,Guangdong Prov Acad Med Sci ^[1] Dept Hepat Surg,Foshan First Peoples Hosp ^[2] Affiliated Hosp 1,Sun Yat Sen Univ ^[3]

关键词 Pembrolizumab Transarterial chemoembolization Lenvatinib Hepatectomy Hepatocellular carcinoma Conversion TRANSARTERIAL CHEMOEMBOLIZATION SALVAGE SURGERY CIRRHOSIS CRITERIA THERAPY TRIAL

发布时间 2022-10-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study

相似文献

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study

相似文献

相关期刊

检索历史清除